Chan Whiting

Chan Whiting is an experienced biotech leader currently serving as Chief Scientific Officer at SLAM BioTherapeutics, focusing on developing innovative ADCs and bispecifics for various life-threatening cancers. Previous roles include Chief Scientific Officer at Deciduous Therapeutics and Chief Development Officer and Head of R&D at Actym Therapeutics, with significant experience as Senior Vice President and Head of R&D at Tempest Therapeutics. Chan has also held pivotal positions at Aduro Biotech, Stanford University, and Qiagen, contributing to cancer immunotherapy and autoimmune research. Chan Whiting holds a Ph.D. in biochemistry, immunology, and infectious diseases from Stanford University, along with a B.S. in Biochemistry from UCLA.